BACKGROUND: Few randomized controlled trials (RCTs) have been performed in patients undergoing pancreaticoduodenectomy (PD). An important factor contributing to this is the large number of patients needed to adequately power RCTs for relevant clinical single endpoints. A PD-specific composite endpoint (CEP) could solve this problem. The aim of the present study was to develop a PD-specific CEP, consisting of complications related to PD, allowing reduction in sample sizes and improving the ability to compare outcomes. METHODS: PD-specific CEP components were selected after a systematic review of the literature and consensus between 25 international pancreatic surgeons. Ultimately, prospective cohorts of patients who underwent PD in two high-volume HPB centers (London, UK, and Maastricht, NL) were used to assess the event rate and effect of implementing a PD-specific CEP. RESULTS: From a total of 18 single-component endpoints, intra-abdominal abscess, sepsis, post-PD hemorrhage, bile leakage, gastrojejunostomy leakage, leakage of the pancreatic anastomosis, delayed gastric emptying, and operative mortality within 90 days were selected to be included the PD-specific CEP. All eight components had consensus definitions and a Dindo-Clavien classification of 3 or more. The incidence of the PD-specific CEP was 24.7 % in the Maastricht cohort and 23.3 % in the London cohort. These incidence rates led to a twofold reduction in the theoretical calculated sample size for an adequately powered RCT on PD using this CEP as a primary endpoint. CONCLUSIONS: The proposed PD-specific CEP enables clinical investigators to adequately power RCTs on PD and increases the feasibility, comparability, and utility in meta-analysis.
BACKGROUND: Few randomized controlled trials (RCTs) have been performed in patients undergoing pancreaticoduodenectomy (PD). An important factor contributing to this is the large number of patients needed to adequately power RCTs for relevant clinical single endpoints. A PD-specific composite endpoint (CEP) could solve this problem. The aim of the present study was to develop a PD-specific CEP, consisting of complications related to PD, allowing reduction in sample sizes and improving the ability to compare outcomes. METHODS: PD-specific CEP components were selected after a systematic review of the literature and consensus between 25 international pancreatic surgeons. Ultimately, prospective cohorts of patients who underwent PD in two high-volume HPB centers (London, UK, and Maastricht, NL) were used to assess the event rate and effect of implementing a PD-specific CEP. RESULTS: From a total of 18 single-component endpoints, intra-abdominal abscess, sepsis, post-PD hemorrhage, bile leakage, gastrojejunostomy leakage, leakage of the pancreatic anastomosis, delayed gastric emptying, and operative mortality within 90 days were selected to be included the PD-specific CEP. All eight components had consensus definitions and a Dindo-Clavien classification of 3 or more. The incidence of the PD-specific CEP was 24.7 % in the Maastricht cohort and 23.3 % in the London cohort. These incidence rates led to a twofold reduction in the theoretical calculated sample size for an adequately powered RCT on PD using this CEP as a primary endpoint. CONCLUSIONS: The proposed PD-specific CEP enables clinical investigators to adequately power RCTs on PD and increases the feasibility, comparability, and utility in meta-analysis.
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: Thilo Welsch; Hanna Eisele; Stefanie Zschäbitz; Ulf Hinz; Markus W Büchler; Moritz N Wente Journal: Langenbecks Arch Surg Date: 2011-05-25 Impact factor: 3.445
Authors: Michelle L DeOliveira; Jordan M Winter; Markus Schafer; Steven C Cunningham; John L Cameron; Charles J Yeo; Pierre-Alain Clavien Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Markus K Diener; Christoph M Seiler; Inga Rossion; Jörg Kleeff; Matthias Glanemann; Giovanni Butturini; Ales Tomazic; Christiane J Bruns; Olivier R C Busch; Stefan Farkas; Orlin Belyaev; John P Neoptolemos; Christopher Halloran; Tobias Keck; Marco Niedergethmann; Klaus Gellert; Helmut Witzigmann; Otto Kollmar; Peter Langer; Ulrich Steger; Jens Neudecker; Frederik Berrevoet; Silke Ganzera; Markus M Heiss; Steffen P Luntz; Thomas Bruckner; Meinhard Kieser; Markus W Büchler Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Niels A van der Gaag; Erik A J Rauws; Casper H J van Eijck; Marco J Bruno; Erwin van der Harst; Frank J G M Kubben; Josephus J G M Gerritsen; Jan Willem Greve; Michael F Gerhards; Ignace H J T de Hingh; Jean H Klinkenbijl; Chung Y Nio; Steve M M de Castro; Olivier R C Busch; Thomas M van Gulik; Patrick M M Bossuyt; Dirk J Gouma Journal: N Engl J Med Date: 2010-01-14 Impact factor: 91.245
Authors: David P J van Dijk; Maikel J A M Bakens; Mariëlle M E Coolsen; Sander S Rensen; Ronald M van Dam; Martijn J L Bours; Matty P Weijenberg; Cornelis H C Dejong; Steven W M Olde Damink Journal: J Cachexia Sarcopenia Muscle Date: 2016-10-26 Impact factor: 12.910
Authors: Katherine Davis; Sarah L Gorst; Nicola Harman; Valerie Smith; Elizabeth Gargon; Douglas G Altman; Jane M Blazeby; Mike Clarke; Sean Tunis; Paula R Williamson Journal: PLoS One Date: 2018-02-13 Impact factor: 3.240
Authors: David P J van Dijk; Victor van Woerden; Hamit Cakir; Marcel den Dulk; Steven W M Olde Damink; Cornelis H C Dejong Journal: J Surg Oncol Date: 2017-08-02 Impact factor: 3.454